Alexandria Pharmaceuticals results, Q3 2022
Net profit, assets, equity and cash flow for Q3 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit117 millionEGP
Total assets875 millionEGP
Shareholders' equity630 millionEGP
Operating cash flow193 millionEGP
In short
- Alexandria Pharmaceuticals's net profit for Q3 2022 was about 117 million EGP.
- Total assets at the end of Q3 2022 were about 875 million EGP, and shareholders' equity about 630 million EGP.
- Operating cash flow for Q3 2022 was positive at 193 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit117 million——
Gross profit461 million——
Total assets875 million——
Total liabilities245 million——
Shareholders' equity630 million——
Total liabilities and equity875 million——
Operating cash flow193 million——
Investing cash flow-26.6 million——
Financing cash flow-64.52 million——
Net change in cash102 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy